company background image
CRAD

C-Rad OM:CRAD B Stock Report

Last Price

kr41.15

Market Cap

kr1.4b

7D

-4.2%

1Y

-18.7%

Updated

24 Jun, 2022

Data

Company Financials +
CRAD B fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance4/6
Financial Health6/6
Dividends0/6

CRAD B Stock Overview

C-Rad AB (publ), together with its subsidiaries, develops, manufactures, and sells systems with applications in radiation therapy for the treatment of cancer worldwide.

C-Rad Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for C-Rad
Historical stock prices
Current Share Pricekr41.15
52 Week Highkr67.40
52 Week Lowkr35.00
Beta1.16
1 Month Change0%
3 Month Change-15.59%
1 Year Change-18.68%
3 Year Change12.43%
5 Year Change82.08%
Change since IPO174.33%

Recent News & Updates

May 07
Returns Are Gaining Momentum At C-Rad (STO:CRAD B)

Returns Are Gaining Momentum At C-Rad (STO:CRAD B)

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? One common approach...

Shareholder Returns

CRAD BSE Medical EquipmentSE Market
7D-4.2%5.6%-1.3%
1Y-18.7%-35.0%-23.6%

Return vs Industry: CRAD B exceeded the Swedish Medical Equipment industry which returned -35% over the past year.

Return vs Market: CRAD B exceeded the Swedish Market which returned -23.6% over the past year.

Price Volatility

Is CRAD B's price volatile compared to industry and market?
CRAD B volatility
CRAD B Average Weekly Movement6.9%
Medical Equipment Industry Average Movement8.4%
Market Average Movement7.4%
10% most volatile stocks in SE Market12.2%
10% least volatile stocks in SE Market4.7%

Stable Share Price: CRAD B is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: CRAD B's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200470Tim Thurnhttps://www.c-rad.se

C-Rad AB (publ), together with its subsidiaries, develops, manufactures, and sells systems with applications in radiation therapy for the treatment of cancer worldwide. The company operates through two segments, Positioning and Imaging. Its products include Sentinel 4D CT, a laser-based optical surface scanning system; Catalyst, a 4D surface image guided radiation therapy (SIGRT) solution; Catalyst HD, an SIGRT solution on stereotactic radiation therapy for online patient tracking before and during treatment delivery; Catalyst+, an SIGRT solution for high precision patient positioning, intra-fraction motion management, and respiratory gating; and Catalyst+ HD, a solution for high precision patient positioning, intra-fraction motion management, and respiratory gating for conventional and stereotactic treatment delivery.

C-Rad Fundamentals Summary

How do C-Rad's earnings and revenue compare to its market cap?
CRAD B fundamental statistics
Market Capkr1.39b
Earnings (TTM)kr20.70m
Revenue (TTM)kr257.45m

67.1x

P/E Ratio

5.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CRAD B income statement (TTM)
Revenuekr257.45m
Cost of Revenuekr87.02m
Gross Profitkr170.43m
Other Expenseskr149.73m
Earningskr20.70m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Jul 21, 2022

Earnings per share (EPS)0.61
Gross Margin66.20%
Net Profit Margin8.04%
Debt/Equity Ratio0%

How did CRAD B perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is CRAD B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CRAD B?

Other financial metrics that can be useful for relative valuation.

CRAD B key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5x
Enterprise Value/EBITDA40x
PEG Ratio1.6x

Price to Earnings Ratio vs Peers

How does CRAD B's PE Ratio compare to its peers?

CRAD B PE Ratio vs Peers
The above table shows the PE ratio for CRAD B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average856.8x

Price-To-Earnings vs Peers: CRAD B is good value based on its Price-To-Earnings Ratio (67.1x) compared to the peer average (856.8x).


Price to Earnings Ratio vs Industry

How does CRAD B's PE Ratio compare vs other companies in the Medical Equipment Industry?

Price-To-Earnings vs Industry: CRAD B is expensive based on its Price-To-Earnings Ratio (67.1x) compared to the Swedish Medical Equipment industry average (35.8x)


Price to Earnings Ratio vs Fair Ratio

What is CRAD B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CRAD B PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio67.1x
Fair PE Ratio50.7x

Price-To-Earnings vs Fair Ratio: CRAD B is expensive based on its Price-To-Earnings Ratio (67.1x) compared to the estimated Fair Price-To-Earnings Ratio (50.7x).


Share Price vs Fair Value

What is the Fair Price of CRAD B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CRAD B (SEK41.15) is trading below our estimate of fair value (SEK99.15)

Significantly Below Fair Value: CRAD B is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: CRAD B is poor value based on its PEG Ratio (1.6x)


Discover undervalued companies

Future Growth

How is C-Rad forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


41.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CRAD B's forecast earnings growth (41.9% per year) is above the savings rate (0.3%).

Earnings vs Market: CRAD B's earnings (41.9% per year) are forecast to grow faster than the Swedish market (9.8% per year).

High Growth Earnings: CRAD B's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: CRAD B's revenue (15.4% per year) is forecast to grow faster than the Swedish market (5.6% per year).

High Growth Revenue: CRAD B's revenue (15.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CRAD B's Return on Equity is forecast to be high in 3 years time (22.3%)


Discover growth companies

Past Performance

How has C-Rad performed over the past 5 years?

Past Performance Score

4/6

Past Performance Score 4/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


44.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CRAD B has high quality earnings.

Growing Profit Margin: CRAD B's current net profit margins (8%) are higher than last year (7.5%).


Past Earnings Growth Analysis

Earnings Trend: CRAD B has become profitable over the past 5 years, growing earnings by 44% per year.

Accelerating Growth: CRAD B's earnings growth over the past year (20.6%) is below its 5-year average (44% per year).

Earnings vs Industry: CRAD B earnings growth over the past year (20.6%) exceeded the Medical Equipment industry 6.3%.


Return on Equity

High ROE: CRAD B's Return on Equity (9%) is considered low.


Discover strong past performing companies

Financial Health

How is C-Rad's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: CRAD B's short term assets (SEK260.5M) exceed its short term liabilities (SEK64.9M).

Long Term Liabilities: CRAD B's short term assets (SEK260.5M) exceed its long term liabilities (SEK6.0M).


Debt to Equity History and Analysis

Debt Level: CRAD B is debt free.

Reducing Debt: CRAD B has no debt compared to 5 years ago when its debt to equity ratio was 19.2%.

Debt Coverage: CRAD B has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: CRAD B has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is C-Rad current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate CRAD B's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CRAD B's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CRAD B's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CRAD B's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CRAD B has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

Tim Thurn (40 yo)

8.92yrs

Tenure

kr2,196,000

Compensation

Mr. Tim Thurn has been the Chief Executive Officer of C-Rad AB since July 1, 2013 and serves as its President since July 1, 2013. Mr. Thurn has been the Chief Executive Officer of C-Rad Imaging AB since 20...


CEO Compensation Analysis

Compensation vs Market: Tim's total compensation ($USD216.86K) is about average for companies of similar size in the Swedish market ($USD228.60K).

Compensation vs Earnings: Tim's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: CRAD B's management team is considered experienced (2.5 years average tenure).


Board Members

Experienced Board: CRAD B's board of directors are considered experienced (5.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CRAD B insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

C-Rad AB (publ)'s employee growth, exchange listings and data sources


Key Information

  • Name: C-Rad AB (publ)
  • Ticker: CRAD B
  • Exchange: OM
  • Founded: 2004
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: kr1.390b
  • Shares outstanding: 33.77m
  • Website: https://www.c-rad.se

Number of Employees


Location

  • C-Rad AB (publ)
  • SjukhusvAegen 12K
  • Uppsala
  • Uppsala County
  • 753 09
  • Sweden

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/24 00:00
End of Day Share Price2022/06/23 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.